Volume 32, Issue 8 (November 2021)
Studies in Medical Sciences 2021, 32(8): 631-637 |
Back to browse issues page
Assistant Professor of Biostatistics, Urmia University of Medical Sciences, Urmia, Iran. (Corresponding Author) , alinejad.v@umsu.ac.ir@gmail.com
Abstract: (2240 Views)
Background & Aims: Considering the complications of pregnancy such as abortion, preeclampsia, preterm delivery and intrauterine death, identifying mothers who are at risk of pregnancy complications can help control and improve pregnancy outcomes. The goal of this perinatal care study was to achieve good pregnancy outcomes that considered maternal health and good fetal outcomes.
Materials & Methods: In the present case-control study, 400 pregnant women who were referred to the prenatal clinics of Motahari Hospital in Urmia in the second half of 1398 and the first half of 1399, as well as mothers who were in the first 3 months of pregnancy, were selected and included in the study. They were divided into two groups of 200. The case group consisted of 200 mothers with a serum PAPP-A level of less than 0.4 and no aspirin. The control group also included 200 mothers with serum PAPP-A levels higher than 0.4. Pregnancy complications including preeclampsia, gestational hypertension, placental abruption, fetal growth restriction and intrauterine death were compared between groups.
Results: The results of this study showed that preeclampsia due to PTL (Preterm Labor) (P = 0.001) and also due to IUFD (Intrauterine Fetal Death) (P = 0.049) had a significant relationship with low serum PAPP-A, while Low serum PAPP-A level was not significantly associated with preeclampsia, IUGR (intrauterine growth restriction) and gestational hypertension.
Conclusions: Measurement of serum PAPP-A alone cannot predict pregnancy complications such as preeclampsia, IUGR, and preterm delivery, and it seems that should be considered along with other clinical and paraclinical indices that are useful in predicting these complications in pregnant mothers.
Materials & Methods: In the present case-control study, 400 pregnant women who were referred to the prenatal clinics of Motahari Hospital in Urmia in the second half of 1398 and the first half of 1399, as well as mothers who were in the first 3 months of pregnancy, were selected and included in the study. They were divided into two groups of 200. The case group consisted of 200 mothers with a serum PAPP-A level of less than 0.4 and no aspirin. The control group also included 200 mothers with serum PAPP-A levels higher than 0.4. Pregnancy complications including preeclampsia, gestational hypertension, placental abruption, fetal growth restriction and intrauterine death were compared between groups.
Results: The results of this study showed that preeclampsia due to PTL (Preterm Labor) (P = 0.001) and also due to IUFD (Intrauterine Fetal Death) (P = 0.049) had a significant relationship with low serum PAPP-A, while Low serum PAPP-A level was not significantly associated with preeclampsia, IUGR (intrauterine growth restriction) and gestational hypertension.
Conclusions: Measurement of serum PAPP-A alone cannot predict pregnancy complications such as preeclampsia, IUGR, and preterm delivery, and it seems that should be considered along with other clinical and paraclinical indices that are useful in predicting these complications in pregnant mothers.
Type of Study: Research |
Subject:
زنان و زایمان
References
1. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53(5): 812-8. [DOI:10.1161/HYPERTENSIONAHA.108.127977] [PMID]
2. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet. Gynecol 2003;102(1): 181-192. [DOI:10.1016/S0029-7844(03)00475-7]
3. Moore KL, Persaud T. The Developing Human: Clinically Oriented Embryology [slides]: Saunders; 1993. [URL]
4. Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Research Part A: Clin Mol Teratol 2012;94(6): 417-23. [DOI:10.1002/bdra.23014] [PMID]
5. Martin Jr JN, Owens MY, Keiser SD, Parrish MR, Tam Tam KB, Brewer JM, et al. Standardized Mississippi Protocol treatment of 190 patients with HELLP syndrome: slowing disease progression and preventing new major maternal morbidity. Hypertens Pregnancy. 2012;31(1): 79-90. [DOI:10.3109/10641955.2010.525277] [PMID]
6. Conde-Agudelo A, Romero R, Roberts JM. Tests to predict preeclampsia. Chesley's hypertensive disorders in pregnancy: Elsevier; 2015. p. 221-251. [DOI:10.1016/B978-0-12-407866-6.00011-0]
7. Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. Am J Obstet Gynecol 2016;214(5): 619. [DOI:10.1016/j.ajog.2015.11.016] [PMID]
8. Cook CM, Ellwood D. A longitudinal study of the cervix in pregnancy using transvaginal ultrasound. BJOG: Br J Obstet Gynaecol 1996;103(1): 16-8. [DOI:10.1111/j.1471-0528.1996.tb09509.x] [PMID]
9. Andrews WW, Sibai BM, Thom EA, Dudley D, Ernest J, McNellis D, et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet. Gynecol 2003;101(5): 847-55. [DOI:10.1097/00006250-200305000-00005] [PMID]
10. Unterscheider J, O'Donoghue K, Malone FD. Guidelines on fetal growth restriction: a comparison of recent national publications. Am. J. Perinatol 2015;32(04): 307-716. [DOI:10.1055/s-0034-1387927] [PMID]
11. De Jesus LC, Pappas A, Shankaran S, Li L, Das A, Bell EF, et al. Outcomes of small for gestational age infants born at< 27 weeks' gestation. J Pediatr 2013;163(1): 55-60. [DOI:10.1016/j.jpeds.2012.12.097] [PMID] [PMCID]
12. Briand V, Saal J, Ghafari C, Huynh B-T, Fievet N, Schmiegelow C, et al. Fetal growth restriction is associated with malaria in pregnancy: a prospective longitudinal study in Benin. J Infect Dis 2016; 214(3): 25-417. [DOI:10.1093/infdis/jiw158] [PMID]
13. Fialova L, Malbohan I. Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects. Bratislavske lek listy 2002;103(6): 194-205. [Google Scholar]
14. McIntyre J, Hsi B, Faulk WP, Klopper A, Thomson R. Immunological studies of the human placenta: functional and morphological analysis of pregnancy-associated plasma protein A (PAPP-A). Immunology 1981;44(3): 577. [PMID] [PMCID]
15. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999;96(6): 3149-3153. [DOI:10.1073/pnas.96.6.3149] [PMID] [PMCID]
16. Irwin J, Suen L-F, Martina N, Mark S, Giudice L. Role of the IGF system in trophoblast invasion and pre-eclampsia.Hum Reprod 1999;14(suppl_2): 90-98. [DOI:10.1093/humrep/14.suppl_2.90] [PMID]
17. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002;87(4): 1762-1767. [DOI:10.1210/jcem.87.4.8430] [PMID]
18. Quattrocchi T, Baviera G, Pochiero T, Basile F, Rizzo L, Santamaria A, et al. Maternal serum PAPP-A as an early marker of obstetric complications? Fetal Diagn Ther 2015;37(1): 33-36. [DOI:10.1159/000365147] [PMID]
19. R Katie Morris, Ashwini Bilagi, Pooja Devani , Mark D Kilby. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn 2017 Mar;37(3): 253-265. [DOI:10.1002/pd.5001] [PMID]
20. Maryam Sadat Hoseini , Samaneh Sheibani , Mehrdad Sheikhvatan. The evaluating of pregnancy-associated plasma protein-A with the likelihood of small for gestational age. Obstet Gynecol Sci 2020 May;63(3): 225-230. [DOI:10.5468/ogs.2020.63.3.225] [PMID] [PMCID]
21. Roman V Kapustin, Tatyana K Kascheeva , Elena N Alekseenkova , Elizaveta V Shelaeva. Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?. J Matern Fetal Neonatal Med 2020 Mar 30;1-7. [Google Scholar]
22. Biyuan He, Chunhong Hu, Yuqing Zhou. First-trimester screening for fetal growth restriction using Doppler color flow analysis of the uterine artery and serum PAPP-A levels in unselected pregnancies. J Matern Fetal Neonatal Med 2021 Dec;34(23): 3857-3861. [DOI:10.1080/14767058.2019.1701646] [PMID]
23. Ning Yu , Hongyan Cui, Xu Chen , Ying Chang. First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction. Taiwan J Obstet Gynecol 2017 Jun;56(3): 358-361. [DOI:10.1016/j.tjog.2017.01.009] [PMID]
24. Ximena Carolina Romero Infante , Montserrat Uriel, Alexandra Porras Ramírez , Sara Rincón Franco. Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population. J Obstet Gynaecol Res 2021 Feb;47(2): 765-773. [DOI:10.1111/jog.14605] [PMID]
25. Zeba Khanam, Pratima Mittal, Jyotsna Suri. Does the Addition of Serum PAPP-A and β-hCG Improve the Predictive Value of Uterine Artery Pulsatility Index for Preeclampsia at 11-14 Weeks of Gestation? A Prospective Observational Study. J Obstet Gynaecol India 2021 Jun;71(3): 226-234. [DOI:10.1007/s13224-020-01420-7] [PMID] [PMCID]
26. X-W Sun, X-H Li, C Zhang, F-Q Meng, Y-G Xing, Y Ding. Correlation analysis of serum placental growth factor, pregnancy-related plasma protein-A and disease severity in patients with hypertensive disorder in pregnancy. Eur Rev Med Pharmacol Sci 2021 Feb;25(4): 1788-1795. [Google Scholar]
27. L Noël , G P Guy, S Jones, K Forenc, E Buck , A T Papageorghiou, et al. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?. Ultrasound Obstet Gynecol 2021 Oct;58(4): 540-545. [DOI:10.1002/uog.23669] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |